New York State Common Retirement Fund decreased its holdings in Keryx Biopharmaceuticals (NASDAQ:KERX) by 51.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,900 shares of the biopharmaceutical company’s stock after selling 87,079 shares during the period. New York State Common Retirement Fund’s holdings in Keryx Biopharmaceuticals were worth $581,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also bought and sold shares of KERX. Fox Run Management L.L.C. acquired a new position in shares of Keryx Biopharmaceuticals in the third quarter worth $101,000. Principal Financial Group Inc. grew its stake in shares of Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 590 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of Keryx Biopharmaceuticals by 51.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 5,628 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $183,000. Finally, Legal & General Group Plc grew its stake in shares of Keryx Biopharmaceuticals by 8.5% in the second quarter. Legal & General Group Plc now owns 28,205 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 2,220 shares in the last quarter. Institutional investors and hedge funds own 64.82% of the company’s stock.
Keryx Biopharmaceuticals (NASDAQ KERX) opened at $4.71 on Friday. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. The company has a market cap of $560.50, a price-to-earnings ratio of -3.14 and a beta of 4.92. Keryx Biopharmaceuticals has a 12 month low of $4.33 and a 12 month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $15.00 million for the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The business’s revenue for the quarter was up 138.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.39) EPS. analysts expect that Keryx Biopharmaceuticals will post -1.36 EPS for the current year.
Several equities analysts have commented on KERX shares. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Stifel Nicolaus lowered their target price on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and an average target price of $7.35.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2018/01/07/new-york-state-common-retirement-fund-reduces-holdings-in-keryx-biopharmaceuticals-kerx.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals (NASDAQ:KERX).
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.